Abstract:
Cholecystokinin (CCK) is a peptide originally discovered in the gastrointestinal tract but is also found in high density in the mammalian brain. The Cāterminal sulfated octapeptide fragment of CCK8 constitutes one of the major neuropeptides in the brain. CCK8, interacting with nanomolar affinities with two different receptors designated CCK1 and CCK2, has been shown to be involved in numerous physiological functions and is involved in the modulation and control of multiple central functions. In particular, CCK is involved in the neurobiology of anxiety, depression, psychosis, cognition, nociception, and feeding behavior. The functional role of CCK has been facilitated thanks to the development of potent and selective CCK receptor antagonists and agonists. In this chapter, the strategies followed to design these probes, and their use to study the anatomy of CCK pathways, the neurochemical and pharmacological properties of this peptide, and the clinical perspectives offered by manipulation of the CCK system are reported.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ACC:
-
anterior cingulate cortex
- APA:
-
aminopeptidase A
- CCK:
-
cholecystokinin
- CCKLM:
-
CCKālike material
- CNS:
-
central nervous system
- GABA:
-
gammaāaminobutyric acid
- GPCR:
-
Gāproteinācoupled receptor
- IP3:
-
inositol 1,4,5ātriphosphate
- JNK:
-
cāJunāNH2āterminal kinases
- LETO:
-
LongāEvans Tokushima Otsuka
- MAPK:
-
mitogenāactivated protein kinase
- NTS:
-
nucleus tractus solitarius
- OLETF:
-
Otsuka LongāEvans Tokushima fatty
- PC:
-
prohormone convertase
- PKA:
-
protein kinase A
- PKC:
-
protein kinase C
- PLA2:
-
phospholipase A2
- PLC:
-
phospholipase C
- PTX:
-
pertussis toxin
- TM:
-
transmembraneāspanning domains
- VTA:
-
ventral tegmental area
References
Abramov U, Raud S, Koks S, Innos J, Kurrikoff K, et al 2004. Targeted mutation of CCK(2) receptor gene antagonises behavioural changes induced by social isolation in female, but not in male mice. Behav Brain Res 155: 1ā11.
Aquino CJ, Armour DR, Berman JM, Birkemo LS, Carr RAE, et al 1996. Discovery of 1,5ābenzodiazepines with peripheral cholecystokinin (CCKāA) receptor agonist activity. 1. Optimization of the agonist ātriggerā. J Med Chem 39: 562ā569.
Baamonde A, DaugĆ© V, RuizāGayo M, Fulga IG, Turcaud S, et al 1992. Antidepressantātype effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid Ī“ and dopamine D1 receptor stimulation. Eur J Pharmacol 216: 157ā166.
Baber NS, Dourish CT, Hill DR. 1989. The role of CCK, caerulein, and CCK antagonists in nociception. Pain 39: 307ā328.
Barrett RW, Steffey ME, Wolfram CAW. 1989. TypeāA CCK receptors in CHP 212 neuroblastoma cells: evidence for association with G protein and activation of phosphoinositide hydrolysis. Mol Pharmacol 35: 394ā400.
Becker C, Thiebot MH, Touitou Y, Hamon M, Cesselin F, et al 2001. Enhanced cortical extracellular levels of cholecystokininālike material in a model of anticipation of social defeat in the rat. J Neurosci 21: 262ā269.
Beinfeld MC. 2003a. Biosynthesis and processing of pro CCK: recent progress and future challenges. Life Sci 72: 747ā757.
Beinfeld MC. 2003b. What we know and what we need to know about the role of endogenous CCK in psychostimulant sensitization. Life Sci 73: 643ā654.
Beinfeld MC, Garver DL. 1991. Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response. Prog Neuropsychopharmacol Biol Psychiatry 15: 601ā609.
Bellier B, Crete D, Million ME, Beslot F, Bado A, et al 2004. New CCK(2) agonists confirming the heterogeneity of CCK(2) receptors: characterisation of BBL454. Naunyn Schmiedebergs Arch Pharmacol 370: 404ā413.
Ben Natan L, Chaillet P, Lecomte JM, MarƧais H, Uchida G, et al 1984. Involvement of endogenous enkephalins in the mouse ābehavioral despairā test. Eur J Pharmacol 97: 301ā304.
Benoliel JJ, Bourgoin S, Mauborgne A, Legrand JC, Hamon M, et al 1991. Differential inhibitory/stimulatory modulation of spinal CCK release by mu and delta opioid agonists, and selective blockade of muādependent inhibition by kappa receptor stimulation. Neurosci Lett 124: 204ā207.
Benoliel JJ, Mauborgne A, Bourgoin S, Legrand JC, Hamon M, et al 1992. Opioid control of the in vitro release of CCKālike material from the rat substantia nigra. J Neurochem 58: 916ā922.
Bernad N, Burgaud BG, Horwell DC, Lewthwaite RA, Martinez J, et al 2000. The design and synthesis of the high efficacy, nonāpeptide CCK1 receptor agonist PD170292. Bioorg Med Chem Lett 10: 1245ā1248.
Bi S, Moran TH. 2002. Actions of CCK in the controls of food intake and body weight: lessons from the CCKāA receptor deficient OLETF rat. Neuropeptides 36: 171ā181.
Bignon E, Bachy A, Boigegrain R, Brodin R, Cottineau M, et al 1999. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies. J Pharmacol Exp Ther 289: 742ā751.
Blommaert AG, Weng JH, Dorville A, McCort I, Ducos B, et al 1993. Cholecystokinin peptidomimetics as selective CCKāB antagonists: design, synthesis, and in vitro and in vivo biochemical properties. J Med Chem 36: 2868ā2877.
Blommaert AGS, DhĆ“tel H, Ducos B, Durieux C, Goudreau N, Bado A, Garbay C, Roques BP. 1997. Structureābased design of new constrained cyclic agonists of the cholecystokinin CCKāB receptor. J Med Chem 40: 647ā658.
Bock MG, DiPardo RM, Evans BE, Rittle KE, Whitter WL, et al 1989. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: Lā365,260. J Med Chem 32: 13ā16.
Boden PR, Higginbottom M, Hill DR, Horwell DC, Hughes J, et al 1993. Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCKāA and CCKāB selective and āmixedā CCKāA/CCKāB antagonists. J Med Chem 36: 552ā565.
Bourin M, Malinge M, Vasar E, Bradwejn J. 1996. Two faces of cholecystokinin: anxiety and schizophrenia. Fundam Clin Pharmacol 10: 116ā126.
Bradwejn J, de Montigny C. 1984. Benzodiazepines antagonize cholecystokinināinduced activation of rat hippocampal neurons. Nature 312: 363ā364.
Bradwejn J, de Montigny C. 1985. Effects of PK 8165, a partial benzodiazepine receptor agonist, on cholecystokinināinduced activation of hippocampal pyramidal neurons: a microiontophoretic study in the rat. Eur J Pharmacol 112: 415ā418.
Bradwejn J, Koszycki D. 2001. Cholecystokinin and panic disorder: past and future clinical research strategies. Scand J Clin Lab Invest Suppl 234: 19ā27.
Bradwejn J, Koszycki D, Payeur R, Bourin M, Borthwick H. 1992. Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Am J Psychiatry 149: 962ā964.
Bradwejn J, Koszycki D, Shriqui C. 1991. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch Gen Psychiatry 48: 603ā610.
Bush DE, DeSousa NJ, Vaccarino FJ. 1999. Selfāadministration of intravenous amphetamine: effect of nucleus accumbens CCKB receptor activation on fixedāratio responding. Psychopharmacology (Berl) 147: 331ā334.
Cain BM, Connolly K, Blum A, Vishnuvardham D, Marchand JE, et al 2003. Distribution and colocalization of cholecystokinin with the prohormone convertase enzymes PC1, PC2, and PC5 in rat brain. J Comp Neurol 467: 307ā325.
Cain BM, Connolly K, Blum AC, Vishnuvardhan D, Marchand JE, et al 2004. Genetic inactivation of prohormone convertase (PC1) causes a reduction in cholecystokinin (CCK) levels in the hippocampus, amygdala, pons and medulla in mouse brain that correlates with the degree of colocalization of PC1 and CCK mRNA in these structures in rat brain. J Neurochem 89: 307ā313.
Carruthers B, Dawbarn D, De Quidt M, Emson PC, Hunter J, et al 1984. Changes in neuropeptide content of amygdala in schizophrenia. Br J Pharmacol 81(Suppl): 190P.
Chang RSL, Lotti VJ, Monaghan RL, Birnbaum J, Stapley EO, et al 1985. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science 230: 177ā179.
Charpentier B, Dor A, Roy P, England P, Pham H, et al 1989. Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors. J Med Chem 31: 1184ā1190.
Charpentier B, Durieux C, PĆ©laprat D, Dor A, Reibaud M, et al 1988b. Enzymeāresistant CCK analogs with high affinities for central receptors. Peptides 9: 835ā841.
Charpentier B, PĆ©laprat D, Durieux C, Dor A, Reibaud M, et al 1988a. Cyclic cholecystokinin analogues with high selectivity for central receptors. Proc Natl Acad Sci USA 85: 1968ā1972.
Charrier D, Dangoumau L, Puech AJ, Hamon M, Thiebot MH. 1995. Failure of CCK receptor ligands to modify anxietyārelated behavioural suppression in an operant conflict paradigm in rats. Psychopharmacology (Berl) 121: 127ā134.
Chen DY, Deutsch JA, Gonzalez MF, Gu Y. 1993. The induction and suppression of cāfos expression in the rat brain by cholecystokinin and its antagonist Lā364,718. Neurosci Lett 149: 91ā94.
Corringer PJ, Weng JH, Ducos B, Durieux C, Boudeau P, et al 1993. CCKāB agonist or antagonist activities of structurally hindered and peptidaseāresistant BocāCCK4 derivatives. J Med Chem 36: 166ā172.
Corwin RL, Gibbs J, Smith GP. 1991. Increased food intake after type A but not type B cholecystokinin receptor blockade. Physiol Behav 50: 255ā258.
CoudorĆ©āCiviale MA, Courteix C, Fialip J, Boucher M, Eschalier A. 2000. Spinal effect of the cholecystokinināB receptor antagonist CIā988 on hyperalgesia, allodynia and morphineāinduced analgesia in diabetic and mononeuropathic rats. Pain 88: 15ā22.
CoudorĆ©āCiviale MA, Meen M, FourniĆ©āZaluski MC, Boucher M, Roques BP, et al 2001. Enhancement of the effects of a complete inhibitor of enkephalinācatabolizing enzymes, RB 101, by a cholecystokinināB receptor antagonist in diabetic rats. Br J Pharmacol 133: 179ā185.
Crawley JN. 1985. Comparative distribution of cholecystokinin and other neuropeptides. Why is this peptide different from all other peptides? Ann NY Acad Sci 448: 1ā8.
Crawley JN, Corwin RL. 1994. Biological actions of cholecystokinin. Peptides 15: 731ā755.
Crespi F. 1998. The role of cholecystokinin (CCK), CCKāA or CCKāB receptor antagonists in the spontaneous preference for drugs of abuse (alcohol or cocaine) in naive rats. Methods Find Exp Clin Pharmacol 20: 679ā697.
Dabrowski A, Grady T, Logsdon CD, Williams JA. 1996. Jun kinases are rapidly activated by cholecystokinin in rat pancreas both in vitro and in vivo. J Biol Chem 271: 5686ā5690.
DaugĆ© V, Roques BP. 1995. Opioid and CCK systems in anxiety and reward. Cholecystokinin and anxiety: from neuron to behavior. Bradwejn J, Vasar E, editors. Austin: RG Landes Company; pp. 151ā171.
DaugĆ© V, Sebret A, Beslot F, Matsui T, Roques BP. 2001. Behavioral profile of CCK2 receptorādeficient mice. Neuropsychopharmacology 25: 690ā698.
Dawson GR, Rupniak NM, Iversen SD, Curnow R, Tye S, et al 1995. Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs. Psychopharmacology (Berl) 121: 109ā117.
Day HE, McKnight AT, Poat JA, Hughes J. 1994. Evidence that cholecystokinin induces immediate early gene expression in the brainstem, hypothalamus and amygdala of the rat by a CCKA receptor mechanism. Neuropharmacology 33: 719ā727.
de Leeuw AS, den Boer JA, Slaap BR, Westenberg HG. 1996. Pentagastrin has panicāinducing properties in obsessive compulsive disorder. Psychopharmacology 126:339ā344.
De Montigny C. 1989. Cholecystokinin tetrapeptide induces panicālike attacks in healthy volunteers. Arch Gen Psychiatry 46: 511ā517.
De Weerth A, Pisegna JR, Huppi K, Wank SA. 1993. Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor. Biochem Biophys Res Commun 194: 811ā818.
De Wied D, Sigling HO. 2002. Neuropeptides involved in the pathophysiology of schizophrenia and major depression. Neurotox Res 4: 453ā468.
Derrien M, DaugĆ© V, Blommaert A, Roques BP. 1994b. The selective CCKāB agonist, BC 264, impairs socially reinforced memory in the threeāpanel runway test in rats. Behav Brain Res 65: 139ā146.
Derrien M, Durieux M, Roques BP. 1994a. Antidepressantālike effects of CCKāB antagonists in mice: antagonism by naltrindole. Br J Pharmacol 111: 956ā960.
Derrien M, Noble F, Maldonado R, Roques BP. 1993. CholecystokinināA but not cholecystokinināB receptor stimulation induces endogenous opioidādependent antinociceptive effects in the hot plate test in mice. Neurosci Lett 160: 193ā196.
Deschenes RJ, Lorenz LJ, Haun RS, Roos BA, Collier KJ, et al 1984. Cloning and sequence analysis of cDNA encoding rat preprocholecystokinin. Proc Natl Acad Sci USA 81: 726ā730.
DeSousa NJ, Wunderlich GR, De Cabo C, Vaccarino FJ. 1999. The expression of behavioral sensitization to amphetamine: role of CCK(A) receptors. Pharmacol Biochem Behav 62: 31ā37.
Dohlman HG, Thorner J, Caron MG, Lefkowitz RJ. 1991. Model systems for the study of sevenātransmembraneāsegment receptors. Annu Rev Biochem 60: 653ā680.
Dourish CT, O'Neill MF, Couglan J, Kitchener SJ, Hawley D, Iversen SD. 1990. The selective CCKāB antagonist Lā365,260 enhances morphine analgesia and prevents morphine tolerance in rat. Eur J Pharmacol 175: 35ā44.
Dunlop J, Zhang Y, Evans N. 1997. Full and partial agonist activity of Cāterminal cholecystokinin peptides at the cloned human CCKāA receptor expressed in Chinese hamster ovary cells. Peptides 18: 865ā868.
Durieux C, Coppey M, Zajac JM, Roques BP. 1986. Occurrence of two cholecystokinin binding sites in guinea pig brain cortex. Biochem Biophys Res Commun 137: 1167ā1173.
Durieux C, RuizāGayo M, Roques BP. 1991. In vivo binding affinities of cholecystokinin agonists and antagonists determined using the selective CCKāB agonist [3H]pBC 264. Eur J Pharmacol 209: 185ā193.
Emson PC, Lee CM, Rehfeld JF. 1980. Cholecystokinin octapeptide: vesicular localization and calcium dependent release from rat brain in vitro. Life Sci 26: 2157ā2163.
EppingāJordan MP, Markou A, Koob GF. 1998. The dopamine Dā1 receptor antagonist SCH 23390 injected into the dorsolateral bed nucleus of the stria terminalis decreased cocaine reinforcement in the rat. Brain Res 784: 105ā115.
Erel U, Arborelius L, Brodin E. 2004. Increased cholecystokinin release in the rat anterior cingulate cortex during carrageenanāinduced arthritis. Brain Res 1022: 39ā46.
Evans BE, Bock MG, Rittle KE, de Pardo RM, Whitter WL, et al 1986. Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. Proc Natl Acad Sci USA 83: 4922ā4948.
Faris PL, Komisaruk BR, Watkins LR, Mayer DJ. 1983. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219: 310ā312.
Faris PL, McLaughlin CL, Baile CA, Olney JW, Komisaruk BR. 1984. Morphine analgesia potentiated but tolerance not affected by active immunization against cholecystokinin. Science 226: 1215ā1217.
Farmery SM, Owen F, Poulter M, Crow TJ. 1985. Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients. Life Sci 36: 473ā477.
Ferrier IN, Roberts GW, Crow TJ, Johnstone EC, Owens DG, et al 1983. Reduced cholecystokininālike and somatostatinālike immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia. Life Sci 33: 475ā482.
FourniĆ©āZaluski MC, Belleney J, Lux B, Durieux C, GĆ©rard G, et al 1986. Conformational analysis of neuronal cholecystokinin CCK26ā33 and related fragments by 1H NMR spectroscopy, fluorescence transfer measurements and calculations. Biochemistry 25: 3778ā3787.
FourniĆ©āZaluski MC, Coric P, Turcaud S, Lucas E, Noble F, et al 1992. Mixedāinhibitorāprodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes. J Med Chem 35: 2474ā2481.
Frankland PW, Josselyn SA, Bradwejn J, Vaccarino FJ, Yeomans JS. 1997. Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat. J Neurosci 17: 1838ā1847.
Fraser KA, Davison JS. 1993. Mealāinduced cāfos expression in brain stem is not dependent on cholecystokinin release. Am J Physiol Regul Integr Comp Physiol 265: R235āR239.
Fuxe K, Andersson K, Locatelli V, Agnati LF, Hokfelt T, et al 1980. Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection. Eur J Pharmacol 67: 329ā331.
Galas MC, Bernard N, Martinez J. 1992. Pharmacological studies on CCKāB receptors in guinea pig synaptoneurosomes. Eur J Pharmacol 226: 35ā41.
Gall C, Lauterborn J, Burks D, Seroogy K. 1987. Coālocalization of enkephalins and cholecystokinin in discrete areas of rat brain. Brain Res 403: 403ā408.
Gaudreau P, St. Pierre S, Pert CB, Quirion R. 1985. Cholecystokinin receptors in mammalian brain: a comparative characterization and visualization. Ann NY Acad Sci 448: 198ā219.
Geracioti TD, Nicholson WE, Orth DN, Ekhator NN, Loosen PT. 1993. Cholecystokinin in human cerebrospinal fluid: concentrations, dynamics, molecular forms and relationship to fasting and feeding in health, depression and alcoholism. Brain Res 629: 260ā268.
Gerhardt P, Voits M, Fink H, Huston JP. 1994. Evidence for mnemotropic action of cholecystokinin fragments BocāCCKā4 and CCKā8S. Peptides 15: 689ā697.
Ghijsen WE, Leenders AG, Wiegant VM. 2001. Regulation of cholecystokinin release from central nerve terminals. Peptides 22: 1213ā1221.
GibertāRahola J, Tejedor P, Chover AJ, Payana M, Rodriguez MM, et al 1990. RB 38B, a selective endopeptidase inhibitor, induced several of escape deficits caused by inescapable shock pretreatment in rats. Eur J Pharmacol 183: 2317ā2325.
Goltermann NR, StengaardāPedersen K, Rehfeld JF, Christensen NJ. 1981. Newly synthesized cholecystokinin in subcellular fractions of the rat brain. J Neurochem 36: 959ā965.
Goudreau N, Weng JH, Roques BP. 1994. Conformational analysis of CCKāB agonists using 1HāNMR and restrained molecular dynamics: comparison of biologically active BocāTrpā(NMe)NleāAspāPheāNH2 and inactive BocāTrpā(NMe)PheāAspāPheāNH2. Biopolymers 34: 155ā159.
Gully D, FrĆ©hel D, Marcy C, Spinazze A, Lespy L, et al 1993. Peripheral biological activity of SR 27897: a new potent nonāpeptide antagonist of CCKāA receptors. Eur J Pharmacol 232: 13ā19.
Gulpinar MA, Yegen BC. 2004. The physiology of learning and memory: role of peptides and stress. Curr Protein Pept Sci 5: 457ā473.
Gustafsson H, Stiller CO, Brodin E. 2000. Peripheral axotomy increases cholecystokinin release in the rat anterior cingulate cortex. Neuroreport 11: 3345ā3348.
Hadjiivanova C, Belcheva S, Belcheva I. 2003. Cholecystokinin and learning and memory processes. Acta Physiol Pharmacol Bulg 27: 83ā88.
Harhammer R, Schafer U, Henklein P, Ott T, Repke H. 1991. CCKā8ārelated Cāterminal tetrapeptides: affinities for central CCKB and peripheral CCKA receptors. Eur J Pharmacol 209: 263ā266.
Harro J, Marcusson J, Oreland L. 1992. Alterations in brain cholecystokinin receptors in suicide victims. Eur Neuropsychopharmacol 2: 57ā63.
Harro J, Oreland L. 1993. Cholecystokinin receptors and memory: a radial maze study. Pharmacol Biochem Behav 44: 509ā517.
Harro J, Vasar E, Bradwejn J. 1993. Cholecystokinin in animal and human research on anxiety. Trends Pharmacol Sci 14: 244ā249.
Hattori E, Yamada K, Ebihara M, Toyota T, Nankai M, et al 2002. Association study of the short tandem repeat in the 5ā² upstream region of the cholecystokinin gene with mood disorders in the Japanese population. Am J Med Genet 114: 523ā526.
Hendrie CA, Neill JC, Shepherd JK, Dourish CT. 1993. The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice. Physiol Behav 54: 689ā693.
Hendry SH, Jones EG, DeFelipe J, Schmechel D, Brandon C, et al 1984. Neuropeptideācontaining neurons of the cerebral cortex are also GABAergic. Proc Natl Acad Sci USA 81: 6526ā6530.
Henke BR, Aquino CJ, Birkemo LS, Croom DK, Dougherty RW, et al 1997. Optimization of 3ā(1Hāindazolā3āylmethyl)ā1,5ābenzodiazepines as potent, orally active CCKāA agonists. J Med Chem 40: 2706ā2725.
Hernando F, Fuentes JA, FourniĆ©āZaluski MC, Roques BP, RuizāGayo M. 1996. Antidepressantālike effects of CCKāB receptor antagonists: involvement of the opioid system. Eur J Pharmacol 318: 221ā229.
Hernando F, Fuentes JA, Roques BP, RuizāGayo M. 1994. The CCKāB receptor antagonist, Lā365,260, elicits antidepressantātype effects in the forcedāswim test in mice. Eur J Pharmacol 261: 257ā263.
Herranz R. 2003. Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev 23: 559ā605.
Hokfelt T, Rehfeld JF, Skirboll L, Ivemark B, Goldstein M, et al 1980. Evidence for coexistence of dopamine and CCK in mesoālimbic neurones. Nature 285: 476ā478.
Honda T, Wada E, Battey JF, Wank SA. 1993. Differential gene expression of CCKA and CCKB receptors in the rat brain. Mol Cell Neurosci 4: 143ā154.
Horwell DC. 1991. Development of CCKāB antagonists. Neuropeptides 19 (Suppl): 57ā64.
Hosing VG, Schirmacher A, Kuhlenbaumer G, Freitag C, Sand P, et al 2004. CholecystokinināA and cholecystokinināBāreceptor gene polymorphisms in panic disorder. J Neural Transm Suppl 68: 147ā156.
Howbert JJ, Lobb KL, Brown RF, Reel JK, Neel DA, et al 1992. A novel series of nonāpeptide CCK and gastrin antagonists: medicinal chemistry and electrophysiological demonstration of antagonism. Multiple cholecystokinin receptors progress toward CNS therapeutic targets. Dourish CT, Cooper SJ, editors. London: Oxford University Press; pp. 28ā37.
Hull RAD, Shankley NP, Harper EA, Gerskowitch VP, Black JW. 1993. 2āNaphthalenesulphonyl lāaspartylā(2āphenethyl)amide (2āNAP)āa selective cholecystokinin CCKāA receptor antagonist. Br J Pharmacol 108: 734ā740.
Innis RB, Snyder SH. 1980. Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA 77: 6917ā6921.
Ise K, Akiyoshi J, Horinouchi Y, Tsutsumi T, Isogawa K, et al 2003. Association between the CCKāA receptor gene and panic disorder. Am J Med Genet 118B: 29ā31.
Ito H, Sogabe H, Nakarai T, Sato Y, Tomoi M, et al 1994. Pharmacological profile of FKā480, a novel cholecystokinin typeāA receptor antagonist: comparison to loxiglumide. J Pharmacol Exp Ther 268: 571ā575.
Ivy AC, Oldberg E. 1928. A hormone mechanism for gallbladder contraction and evacuation. Am J Physiol 86: 599ā613.
Jagerschmidt A, Popovici T, O'Donohue M, Roques BP. 1994. Identification and characterization of various cholecystokinin B receptor mRNA forms in rat brain tissue and partial determination of the cholecystokinin B receptor gene structure. J Neurochem 63: 1199ā1206.
Jensen RT, Huang SC, von Schrenck T, Wank SA, Gardner JD. 1990. Cholecystokinin receptor antagonists: ability to distinguish various classes of cholecystokinin receptors. Gastrointestinal endocrinology: receptors and postāreceptor mechanisms. Thompson JT, Townsend CM, Greely GA, Rayford PL, Wooper CW, et al editors. New York: Academic; pp. 95ā113.
Jensen RT, Qian JM, Lin JT, Mantey SA, Pisegna JR, et al 1994. Distinguishing multiple CCK receptor subtypes: studies with guinea pig chief cells and transfected human CCK receptors. Ann NY Acad Sci 713: 88ā106.
Jorpes JE, Mutt V. 1966. Cholecystokinin and pancreozymin, one single hormone? Acta Physiol Scand 66: 196.
Kariya K, Tanaka J, Nomura M. 1994. Systemic administration of CCKā8S, but not CCKā4, enhances dopamine turnover in the posterior nucleus accumbens: a microdialysis study in freely moving rats. Brain Res 657: 1ā6.
Kennedy JL, Bradwejn J, Koszycki D, King N, Crowe R, et al 1999. Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry 4: 284ā285.
Khaznadar T, David C, Crete D, FourniĆ©āZaluski MC, Roques BP, et al 1997. Aminopeptidase A involved in the inactivation of endogenous CCK8: a microdialysis study. J Neuropsychopharmacol 11: A50.
Knapp RJ, Vaughn LK, Fang SN, Bogert CL, Yamamura MS, et al 1990. A new, highly selective CCKāB receptor radioligand ([3H][NāmethylāNle28,31]CCK26ā33): evidence for CCKāB receptor heterogeneity. J Pharmacol Exp Ther 255: 1278ā1286.
Kobayashi S, Ohta M, Miyasaka K, Funakoshi A. 1996. Decrease in exploratory behavior in naturally occurring cholecystokinin (CCK)āA receptor gene knockout rats. Neurosci Lett 214: 61ā64.
Koks S, Abramov U, Veraksits A, Bourin M, Matsui T, et al 2003. CCK2 receptorādeficient mice have increased sensitivity of dopamine D2 receptors. Neuropeptides 37: 25ā29.
Koks S, Volke V, Veraksits A, Runkorg K, Sillat T, et al 2001. Cholecystokinin2 receptorādeficient mice display altered function of brain dopaminergic system. Psychopharmacology 158: 198ā204.
Kolodziej SA, Nikiforovich GV, Skeean R, Lignon MF, Martinez J, et al 1995. Acā[3ā and 4āalkylthioproline31]āCCK4 analogs: synthesis, and implication for the CCKāB receptorābound conformation. J Med Chem 38: 137ā149.
Kopin AS, Mathes WF, McBride EW, Nguyen M, AlāHaider W, et al 1999. The cholecystokinināA receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J Clin Invest 103: 383ā391.
Lanaud P, Popovici T, Normand E, Lemoine C, Bloch B, et al 1989. Distribution of CCK mRNA in particular regions (hippocampus, periaqueductal grey and thalamus) of the rat by in situ hybridization. Neurosci Lett 104: 38ā42.
Le Melledo JM, Bradwejn J, Koszycki D, Bichet D. 1995. Premenstrual dysphoric disorder and response to cholecystokininātetrapeptide. Arch Gen Psychiatry 52: 605ā606.
Lemaire M, Piot O, Roques BP, Bƶhme AG, Blanchard JC. 1992. Evidence for an endogenous cholecystokininergic balance in social memory. Neuroreport 3: 925ā932.
LĆ©na I, Simon H, Roques BP, DaugĆ© V. 1999. Opposing effects of two selective CCKāB agonists, on the retrieval phase of a twoātrial memory task after systemic injection in the rat. Neuropharmacology 38: 543ā553.
Lo WWY, Hughes J. 1988. Differential regulation of cholecystokininā and muscarinicāreceptorāmediated phosphoinositide turnover in flow 900 cells. Biochem J 251: 625ā630.
Lƶfberg C, Agren H, Harro J, Oreland L. 1998. Cholecystokinin in CSF from depressed patients: possible relations to severity of depression and suicidal behaviour. Eur Neuropsychopharmacol 8: 153ā157.
Magnuson DSK, Sullivan AF, Simonnet G, Roques BP, Dickenson AH. 1990. Differential interactions of cholecystokinin and FLFQPQRFāNH2 with Ī¼ and Ī“ opioid antinociception in the rat spinal cord. Neuropeptides 16: 213ā218.
Makovec F, Chiste R, Bani M, Pacini MA, Setnikar I, et al 1995. New glutaramic acid derivatives with potent competitive specific cholecystokinināantagonistic activity. Arzneimittelforschung 35: 1048ā1051.
Maldonado R, Valverde O, Ducos B, Blommaert AG, FourniĆ©āZaluski MC, et al 1995. Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKāB antagonist PDā134,308. Br J Pharmacol 114: 1031ā1039.
Marshall FH, Barnes S, Hughes J, Woodruff GN, Hunter JC. 1991. Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. J Neurochem 56: 917ā922.
MartināMartinez M, BartolomĆ©āNebreda JM, GomezāMonterrey I, GonzalezāMuniz R, GarciaāLopez MT, et al 1997. Synthesis and stereochemical structureāactivity relationships of 1,3ādioxoperhydropyrido[1,2āc]pyrimidine derivatives: potent and selective cholecystokinināA receptor antagonists. J Med Chem 40: 3402ā3407.
Matsushita H, Akiyoshi J, Kai K, Ishii N, Kodama K, et al 2003. Spatial memory impairment in OLETF rats without cholecystokinināa receptor. Neuropeptides 37: 271ā276.
Menozzi D, Gardner JD, Maton PN. 1989. Properties of receptors for gastrin and CCK on gastric smooth muscle cells. Am J Physiol 257: G73āG79.
Mercer LD, Beart PM. 1997. Histochemistry in rat brain and spinal cord with an antibody directed at the cholecystokininA receptor. Neurosci Lett 225: 97ā100.
Migaud M, Durieux C, Viereck J, SorocaāLucas E, FourniĆ©āZaluski MC, et al 1996. The in vivo metabolism of cholecystokinin (CCKā8) is essentially ensured by aminopeptidase A. Peptides 17: 601ā607.
Migaud M, Roques BP, Durieux C. 1995. Evidence for a high affinity uptake system for cholecystokinin octapeptide (CCK8) in rat cortical synaptosomes. Eur J Neurosci 7: 1074ā1079.
Millan MJ. 2003. The neurobiology and control of anxious states. Prog Neurobiol 70: 83ā244.
Million ME, LĆ©na I, Da Nascimento S, Noble F, DaugĆ© V, et al 1997. Development of new potent agonists able to interact with two postulated subsites of the cholecystokinin CCKāB receptor. Lett Pept Sci 4: 407ā410.
Miyasaka K, Kobayashi S, Ohta M, Kanai S, Yoshida Y, et al 2002. Anxietyārelated behaviors in cholecystokinināA, āB, and āAB receptor gene knockout mice in the plusāmaze. Neurosci Lett 335: 115ā118.
Miyasaka K, Yoshida Y, Matsushita S, Higuchi S, Shirakawa O, et al 2004. Association of cholecystokinināA receptor gene polymorphisms and panic disorder in Japanese. Am J Med Genet 127B: 78ā80.
Moran TH. 2004. Gut peptides in the control of food intake: 30 years of ideas. Physiol Behav 82: 175ā180.
Moran TH, Robinson PH, Goldrich MS, McHugh PR. 1986. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res 362: 175ā179.
Moran TH, Schwartz GJ. 1994. Neurobiology of cholecystokinin. Crit Rev Neurobiol 9: 1ā28.
Morino P, HerreraāMarschitz M, Castel MN, Ungerstedt U, Varro A, et al 1994. Cholecystokinin in corticoāstriatal neurons in the rat: immunohistochemical studies at the light and electron microscopical level. Eur J Neurosci 6: 681ā692.
Mutt V, Jorpes JE. 1968. Structure of porcine cholecystokinināpancreozymin. Eur J Biochem 6: 156ā162.
Nadzan AM, Garvey DS, Holladay MW, Shiosaki K, Tufano MD, et al 1991. Design of cholecystokinin analogs with high affinity and selectivity for brain receptors. Peptides, chemistry and biology, Proceedings of the 12th American Peptide Symposium. Smith JA, Rivier JE, editors. Leiden, The Netherlands: ESCOM; pp. 101ā102.
Niehoff DL. 1989. Quantitative autoradiographic localization of cholecystokinin receptors in rat and guinea pig brain using 125IāBoltonāHunterāCCK8. Peptides 10: 265ā274.
Nishida A, Miyata K, Tsutsumi R, Yuki H, Akuzawa S, et al 1994. Pharmacological profile of (R)ā1ā[2,3ādihydroā1ā(2ā²āmethylāphenacyl)ā2āoxoā5āphenylā1Hā1,4ābenzodiazepinā3āyl]ā3ā(3āmethylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinināB receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 269: 725ā731.
Noble F, Derrien M, Roques BP. 1993. Modulation of opioid analgesia by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br J Pharmacol 109: 1064ā1070.
Noble F, Wank S, Crawley J, Bradwejn J, Seroogy K, et al 1999. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 51: 745ā781.
O'Dowd B, Hnatowich M, Caron MG, Lefkowitz RJ, Bouvier M. 1988. Siteādirected mutagenesis of the cytoplasmatic domains of the human Ī²ā2 adrenergic receptor. Localization of regions involved in Gāproteināreceptor coupling. J Biol Chem 263: 15985ā15992.
Okubo T, Harada S, Higuchi S, Matsushita S. 2002. Investigation of quantitative trait loci in the CCKAR gene with susceptibility to alcoholism. Alcohol Clin Exp Res 26: 2Sā5S.
Ovchinikov YA, Ablulajew NG, Bogachuck AS. 1988. Two adjacent cysteine residues in the Cāterminal cytoplasmatic fragment of bovine rhodopsin are palmitoylated. FEBS Lett 230: 1ā5.
Ozcelebi F, Miller LJ. 1995. Phosphopeptide mapping of cholecystokinin receptors on agonistāstimulated native pancreatic acinar cells. J Biol Chem 270: 3435ā3441.
Patel S, Smith AJ, Chapman KL, Fletcher AE, Kemp JA, et al 1994. Biological properties of the benzodiazepine amide derivative Lā740,093, a cholecystokinināB/gastrin receptor antagonist with high affinity in vitro and high potency in vivo. Mol Pharmacol 46: 943ā948.
Pendley CE, Fitzpatrick LR, Capolino AJ, Davis MA, Esterline NJ, et al 1995. RP 73870, a gastrin/cholecystokinināB receptor antagonist with potent antiāulcer activity in the rat. J Pharmacol Exp Ther 273: 1015ā1022.
PĆ©laprat D, Broer Y, Studler JM, Peschanski M, Tassin JP, et al 1987. Autoradiography of CCK receptors in the rat brain using [3H]Boc[Nle28,31]CCK27ā33 and [125I]BoltonāHunter CCK8. Neurochem Int 10: 495ā508.
Pohl M, Benoliel JJ, Bourgoin S, Lombard MC, Mauborgne A, et al 1990. Regional distribution of calcitonin geneārelated peptideā, substance Pā, cholecystokininā, Met5āenkephalinā, and dynorphin A (1ā8)ālike materials in the spinal cord and dorsal root ganglia of adult rats: effects of dorsal rhizotomy and neonatal capsaicin. J Neurochem 55: 1122ā1130.
Pommier B, Da Nascimento S, Dumont S, Bellier B, Million E, Garbay C, Roques BP, Noble F. 1999. The CCKāB receptor is coupled to two effector pathways through pertussis toxin sensitive and insensitive G proteins. J Neurochem 73: 281ā288.
Pommier B, MarieāClaire C, Da Nascimento S, Wang HL, Roques BP, et al 2003. Further evidence that the CCK2 receptor is coupled to two transduction pathways using siteādirected mutagenesis. J Neurochem 85: 454ā461.
Pu SF, Zhuang HX, Lu ZB, Wu XR, Han JS. 1994. Cholecystokinin gene expression in rat amygdaloid neurons. Normal distribution and effect of morphine tolerance. Mol Brain Res 21: 183ā189.
Radu D, Ahlin A, Svanborg P, Lindefors N. 2003. Pentagastrin test for anxietyāpsychophysiology and personality. Psychopharmacology (Berl) 166: 139ā145.
Rattray M, De Belleroche J. 1987. Morphine action on cholecystokinin octapeptide release from rat periaqueductal grey slices: sensitization by naloxone. Neuropeptides 10: 189ā200.
Rehfeld JF, Bungaard JR, FriisāHansen L, Goetze JP. 2003. On the tissueāspecific processing of procholecystokinin in the brain and gutāa short review. J Physiol Pharmacol 54 (Suppl. 4): 73ā79.
Rehfeld JF, Holst JJ, Jensen SL. 1982. The molecular nature of vascularly released cholecystokinin from the isolated perfused porcine duodenum. Regul Pept 3: 15ā28.
Rehfeld JF, Lindberg I, FriisāHansen L. 2002. Increased synthesis but decreased processing of neuronal proCCK in prohormone convertase 2 and 7B2 knockout animals. J Neurochem 83: 1329ā1337.
Rehfeld JH, Nielsen FC. 1995. Molecular forms and regional distribution of cholecystokinin in the central nervous system. Cholecystokinin and anxiety. Bradwejn J, Vasar E, editors. Austin: RG Landes Company; pp. 33ā56.
Reidelberger RD, Varga G, Solomon TE. 1991. Effects of selective cholecystokinin antagonists L364,718 and L365,260 on food intake in rats. Peptides 12: 1215ā1221.
Revel L, Ferrari F, Makovec F, Rovati LC, Impicciatore M. 1992. Characterization of antigastrin activity in vivo of CR 2194, a new Rā4ābenzamidoā5āoxoāpentanoic acid derivative. Eur J Pharmacol 216: 217ā224.
Rodriguez RE, Sacristan MP. 1989. In vivo release of CCKā8 from the dorsal horn of the rat: inhibition by DAGOL. FEBS Lett 250: 215ā217.
Roques BP. 2000. Novel approaches to targeting neuropeptide systems. Trends Pharmacol Sci 21: 475ā483.
Roques BP, Noble F. 1995. NIDA Research Monograph, Dual inhibitors of enkephalinādegrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. Discovery of novel opioid medications, Rapaka RS, Sorer H, editors. pp. 104ā145.
Roques BP, Noble F. 1996. Association of enkephalin catabolism inhibitors and CCKāB antagonists: a potential use in the management of pain and opioid addiction. Neurochem Res 21: 1395ā1409.
Roques BP, Noble F, DaugĆ© V, FourniĆ©āZaluski MC, Beaumont A. 1993. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45: 87ā146.
Rose C, Vargas F, Facchinetti P, Bourgeat P, Bambal RB, et al 1996. Characterization and inhibition of a cholecystokinināinactivating serine peptidase. Nature (Lond) 380: 403ā409.
RuizāGayo M, DaugĆ© V, Menant I, BĆ©guĆ© D, Gacel G, et al 1985. Synthesis and biological activity of Boc(Nle28, Nle31)CCK27ā33 a highly potent CCK8 analogue. Peptides 6: 415ā420.
RuizāGayo M, Durieux C, FourniĆ©āZaluski MC, Roques BP. 1992. Stimulation of Ī“ opioid receptors reduces the in vivo binding of the CCKāB selective agonist [3H]pBC264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins. J Neurochem 59: 1805ā1811.
Saito AH, Sankaran H, Goldfine ID, Williams JA. 1980. Cholecystokinin receptors in the brain: characterization and distribution. Science 208: 1155ā1156.
Sanjuan J, Toirac I, Gonzalez JC, Leal C, Molto MD, et al 2004. A possible association between the CCKāAR gene and persistent auditory hallucinations in schizophrenia. Eur Psychiatry 19: 349ā353.
Sankaran H, Goldfine ID, Deveney CW, Wong KY, Williams JA. 1980. Binding of cholecystokinin to high affinity receptors on isolated rat pancreatic acini. J Biol Chem 255: 1849ā1853.
Schalling M, Friberg K, Seroogy K, Riederer P, Bird E, et al 1990. Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and in humans with schizophrenia. Proc Natl Acad Sci USA 87: 8427ā8431.
Sebret A, LĆ©na I, CrĆ©tĆ© D, Matsui T, Roques BP, et al 1999. Rat hippocampal neurons are critically involved in physiological improvement of memory processes induced by cholecystokinināB receptor stimulation. J Neurosci 19: 7230ā7237.
Seidah NG, Chretien M. 1999. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res 848: 45ā62.
Sherrill RG, Berman JM, Birkemo L, Croom DK, Dezube M, et al 2001. 1,4āBenzodiazepine peripheral cholecystokinin (CCKāA) receptor agonists. Bioorg Med Chem Lett 11: 1145ā1148.
Shiosaki K, Graig R, Lin CW, Barrett R, Miller T, et al 1990. Toward development of peptidomimetics: diketopiperazine templates for the TrpāMet segment of CCK4. Peptides: chemistry, structure and biology. Proceedings of the 11th American Peptide Symposium. Rivier JE, Marshall GR, editors. Leiden: ESCOM; pp. 978ā980.
Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J. 1997. Effects of citalopram treatment of behavioural, cardiovascular, and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22: 332ā340.
Shlik J, Koszycki D, Bradwejn J. 1998. Decrease in shortāterm memory function induced by CCKā4 in healthy volunteers. Peptides 19: 969ā975.
SilventeāPoirot S, Escrieut C, Wank SA. 1998. Role of the extracellular domains of the cholecystokinin receptor in agonist binding. Mol Pharmacol 54: 364ā371.
Simmons RD, Blosser JC, Rosamond JR. 1994. FPL 14294: a novel CCKā8 agonist with potent intranasal anorectic activity in the rat. Pharmacol Biochem Behav 47: 701ā708.
Singh L, Field MJ, Hughes J, Menzies R, Oles RJ, et al 1991. The behavioural properties of CIā988, a selective cholecystokininB receptor antagonist. Br J Pharmacol 104: 239ā245.
Singh P, Owlia A, Espeijo R, Dai B. 1995. Novel gastrin receptors mediate mitogenic effects of gastrin processing intermediates of gastrin on Swiss 3T3 fibroblasts. J Biol Chem 270: 8429ā8438.
Smadja C, Maldonado R, Turcaud S, FourniĆ©āZaluski MC, Roques BP. 1995. Opposite role of CCKāA and CCKāB receptors in the modulation of endogenous enkephalins antidepressantālike effects. Psychopharmacology 128: 400ā408.
Smadja C, Ruiz F, Coric P, FournieāZaluski MC, Roques BP, et al 1997. CCKāB receptors in the limbic system modulate the antidepressantālike effects induced by endogenous enkephalins. Psychopharmacology (Berl) 132: 227ā236.
Smith GP, Gibbs J. 1992. The development and proof of the CCK hypothesis of satiety. Multiple cholecystokinin receptors in the CNS. Dourish CT, Cooper SJ, Iversen SD, Iversen LL, editors. Oxford: Oxford University Press; pp. 166ā182.
Tachikawa H, Harada S, Kawanishi Y, Okubo T, Shiraishi H. 1999. Novel polymorphism in the promoter and coding regions of the human cholecystokinin B receptor gene: an association analysis with schizophrenia. Am J Med Genet 88: 700ā704.
Tachikawa H, Harada S, Kawanishi Y, Okubo T, Shiraishi H. 2000. Novel polymorphisms of the human cholecystokinin A receptor gene: an association analysis with schizophrenia. Am J Med Genet 96: 141ā145.
Taghzouti K, LĆ©na I, Dellu F, Roques BP, DaugĆ© V, et al 1999. Cognitive enhancing effects in young and old rats of pBC 264, a selective CCKāB receptor agonist. Psychopharmacology 143: 141ā149.
Takinami Y, Yuki H, Nishida A, Akuzawa S, Uchida A, et al 1997. YF476 is a new potent and selective gastrin/cholecystokinināB receptor antagonist in vitro and in vivo. Aliment Pharmacol Ther 11: 113ā120.
Talkad VD, Fortune KP, Pollo DA, Shah GN, Wank SA, et al 1994. Direct demonstration of three different states of the pancreatic cholecystokinin receptor. Proc Natl Acad Sci USA 91: 1868ā1872.
Taniguchi T, Matsui T, Ito M, Murayama T, Tsukamoto T, et al 1994. CholecystokinināB/gastrin receptor signaling pathway involves tyrosine phosphorylations of p125FAK and p42MAP. Oncogene 9: 861ā867.
TejedorāReal R, Mico JA, Maldonado R, Roques BP, GibertāRahola J. 1993. Effect of a mixed (RB 38A) and selective (RB 38B) inhibitors of enkephalinādegrading enzymes on a model of depression in the rat. Biol Psychiatry 34: 100ā107.
TejedorāReal R, Mico TP, Maldonado R, Roques BP, GibertāRahola J. 1995. Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol Biochem Behav 52: 145ā152.
Tortorici V, Nogueira L, Salas R, Vanegas H. 2003. Involvement of local cholecystokinin in the tolerance induced by morphine microinjections into the periaqueductal gray of rats. Pain 102: 9ā16.
Trivedi BK, Padia JK, Holmes A, Rose S, Wright DS, et al 1998. Second generation āpeptoidā CCKāB receptor antagonists: identification and development of Nā(adamantyloxycarbonyl)āaāmethylā(R)ātryptophan derivative (CIā1015) with an improved pharmacokinetic profile. J Med Chem 41: 38ā45.
Valverde O, Blommaert AGS, FourniĆ©āZaluski MC, Roques BP, Maldonado R. 1995. Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKāB antagonist. Eur J Pharmacol 286: 79ā93.
Valverde O, Maldonado R, FourniĆ©āZaluski MC, Roques BP. 1994. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J Pharmacol Exp Ther 270: 77ā88.
van der Kooy D, Hunt SP, Steinbusch HW, Verhofstad AA. 1981. Separate populations of cholecystokinin and 5āhydroxytryptamineācontaining neuronal cells in the rat dorsal raphe, and their contribution to the ascending raphe projections. Neurosci Lett 26: 25ā30.
van Vliet IM, Westenberg HG, Slaap BR, den Boer JA, Ho Pian KL. 1997. Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls. Biol Psychiatry 42: 76ā78.
Vanderhaeghen JJ, Signeau JC, Gepts W. 1975. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature (Lond) 257: 604ā605.
Vanderschuren LJ, Kalivas PW. 2000. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl) 151: 99ā120.
Verhage M, McMahon HT, Ghijsen WE, Boomsma F, Scholten G, Wiegant VM, Nicholls DG. 1991. Differential release of amino acids, neuropeptides, and catecholamines from isolated nerve terminals. Neuron 6: 517ā524.
Voigt MM, Wang RY, Westfall TC. 1985. The effects of cholecystokinin on the in vivo release of newly synthesized [3H]dopamine from the nucleus accumbens of the rat. J Neurosci 5: 2744ā2749.
Wank SA. 1995. Cholecystokinin receptors. Am J Physiol 269: G628āG646.
Wank SA, Harkins RT, Jensen RT, Shapira H, de Weerth A, et al 1992. Purification, molecular cloning and functional expression of the cholecystokinin receptor from rat pancreas. Proc Natl Acad Sci USA 89: 3125ā3129.
Watkins LR, Kinscheck IB, Mayer DJ. 1984. Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. Science 224: 395ā396.
Wei J, Hemmings GP. 1999. The CCKāA receptor gene possibly associated with auditory hallucinations in schizophrenia. Eur Psychiatry 14: 67ā70.
Wettstein JG, Bueno L, Junien JL. 1994. CCK antagonists: pharmacology and therapeutic interest. Pharmacol Ther 62: 267ā282.
Whiteford HA, Stedman TJ, Welham J, Csernansky JG, Pond SM. 1992. Placeboācontrolled, doubleāblind study of the effects of proglumide in the treatment of schizophrenia. J Clin Psychopharmacol 12: 337ā340.
WiesenfeldāHallin Z, Lucas GA, Alster P, Xu XJ, Hƶkfelt T. 1999. Cholecystokinin/opioid interactions. Brain Res 848: 78ā89.
Willner P. 1990. Animal models of depression: an overview. Pharmacol Ther 45: 425ā455.
Wolkowitz OM, Gertz B, Weingartner H, Beccaria L, Thompson K, et al 1990. Hunger in humans induced by MKā329, a specific peripheralātype cholecystokinin receptor antagonist. Biol Psychiatry 28: 169ā173.
Wunderlich GR, DeSousa NJ, Vaccarino FJ. 2000. Cholecystokinin modulates both the development and the expression of behavioral sensitization to amphetamine in the rat. Psychopharmacology (Berl) 151: 283ā290.
Wunderlich GR, Raymond R, De Sousa NJ, Nobrega JN, Vaccarino FJ. 2002. Decreased CCK(B) receptor binding in rat amygdala in animals demonstrating greater anxietyālike behavior. Psychopharmacology (Berl) 164: 193ā199.
Wunderlich GR, Rotzinger S, Bush DE, DeSousa NJ, Vaccarino FJ. 2004. Cholecystokinin modulation of locomotor behavior in rats is sensitized by chronic amphetamine and chronic restraint stress exposure. Brain Res 1001: 95ā107.
Yule DI, Tseng MJ, Williams JA, Logsdon CD. 1993. A cloned CCKāA receptor transduces multiple signals in response to full and partial agonists. Am J Physiol 265: G999āG1004.
Zarbin MA, Innis RB, Wamsley JK, Snyder SH, Kuhar MJ. 1983. Autoradiographic localization of cholecystokinin receptors in rodent brain. J Neurosci 3: 877ā906.
Zhang LJ, Lu XY, Han JS. 1992. Influences of cholecystokinin octapeptide on phosphoinositide turnover in neonatalārat brain cells. Biochem J 285: 847ā850.
Zhou Y, Sun YH, Zhang ZW, Han JS. 1992. Accelerated expression of cholecystokinin gene in the brain of rats rendered tolerant to morphine. Neuroreport 3: 1121ā1123.
Zhu PC, ThuresonāKlein A, Klein RL. 1986. Exocytosis from large dense cored vesicles outside the active synaptic zones of terminals within the trigeminal subnucleus caudalis: a possible mechanism for neuropeptide release. Neuroscience 19: 43ā54.
Zittel TT, Glatzle J, Kreis M, Starlinger M, Eichner M, et al 1999. CāFos protein expression in the solitary tract correlates with cholecystokinin dose injected and food intake. Brain Res 848: 1ā11.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2006 Springer Science+Business Media, LLC
About this entry
Cite this entry
Noble, F., Roques, B.P. (2006). Cholecystokinin Peptides in Brain Function. In: Lajtha, A., Lim, R. (eds) Handbook of Neurochemistry and Molecular Neurobiology. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-30381-9_24
Download citation
DOI: https://doi.org/10.1007/978-0-387-30381-9_24
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-30348-2
Online ISBN: 978-0-387-30381-9
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences